Percutaneous needle liver biopsy is an important procedure for the diagnosis and evaluation of liver disease and is frequently associated with pain. In this prospective study, we investigated the prevalence and characteristics of this pain syndrome. Fifty-four subjects, who underwent liver biopsy under ultrasound guidance, received 5 mg of diazepam orally 1 h before the procedure and local infiltration with 10 mL of 2% lidocaine just before needle insertion. Outcome measures included the visual analog scale for measuring pain intensity over 24 h, pain localization on a body scheme, and the Spielberger questionnaire for measuring anxiety levels. Forty-seven (84%) of the 54 respondents reported pain 30 min after the biopsy (visual analog scale, 4.2 Ϯ 0.5; mean Ϯ sem), and 21 (39%) reported pain at the 24-h time point. Biopsy site pain was reported by 9 subjects, right shoulder pain by 14, and pain at both sites by 24. Higher pain intensities were reported by women and by subjects with higher anxiety levels. This study indicates that liver biopsy is a painful condition in most patients. Mild anxiolytic treatment plus local anesthetic infiltration seem to produce insufficient analgesia, thus indicating that a more profound analgesic treatment is required for better control of this pain.
(Anesth Analg 2003;96:1392-6) P ercutaneous liver biopsy is an important tool for evaluating liver diseases to establish prognosis and treatment. Patients with inflammatory viral diseases may need to undergo more than one biopsy during the course of their illness. Among the population affected, there is a recognized fear of biopsy because the procedure is regarded as invasive and painful and as one that may lead to serious complications (1, 2) . In recent years, biopsy procedures have been improved in many medical centers and are now performed with specific equipment and under ultrasound guidance rather than in a blinded fashion. One study has shown that the use of ultrasound-guided biopsy also reduced the prevalence of postbiopsy pain from 47.3% to 36.4% and reduced the biopsy pain score from 6.3 Ϯ 1.0 to 4.9 Ϯ 1.2 (3). This is likely to result from the fact the ultrasound provides the operators with more confidence in the approach to the liver, reducing inherent trauma to the subcutaneous tissue and liver capsule.
Despite its prevalence and intensity, little has been done thus far to evaluate the pain associated with liver biopsy or its treatment. The procedure is usually performed under local anesthesia only (3). Conscious sedation, either with midazolam (4, 5) or with nitrous oxide/oxygen inhalation (6), can be effective during and immediately after the biopsy. However, no data are available on the effectiveness of these interventions for the delayed pain, which may last for 24 h after the procedure. Furthermore, according to Sherlock and Dooley (7), "sedation is not given routinely before biopsy as it may interfere with the patient's cooperation." Schiff and Schiff (8) stated that "it is not necessary to premedicate the patient before the biopsy." Thus, not unexpectedly, a nationwide survey in France showed that sedation or premedication was given in only 46% of 2084 biopsies (9) . This study was aimed to investigate liver biopsy-related pain in a broad fashion and to provide data on the prevalence and the characteristics of this pain syndrome, so that better treatment strategies can be developed in the future.
Methods
The study was conducted at the Liver Unit of Rambam Medical Center in Haifa, Israel, between October 1998 and June 1999 and was approved by the local Ethics Committee. All patients provided written, informed consent before enrollment. Patients were considered eligible for the study if they met the following criteria: 1) had an established or suspected liver disease justifying the performance of a liver biopsy, 2) had normal coagulation studies, and 3) were over the age of 18 yr.
A 10-cm blank visual analog scale (VAS) (10) was used to grade the intensity of the subjects' pain. Subjects were asked to mark their pain intensity on this scale, with 0 indicating no pain and 10 indicating the worst imaginable pain. A body scheme was used to indicate the exact location of the pain in the body. In addition, the Spielberger Anxiety Questionnaire (11) was used to measure each subject's state anxiety level before the biopsy.
All patients who met the inclusion criteria were invited to participate in the study. Participants were requested to complete a demographic and general health questionnaire, as well as the Spielberger Anxiety Questionnaire, approximately 2 h before the biopsy. A detailed explanation of how to use the 10-cm blank VAS was given to all subjects by one investigator. Premedication included an oral tablet of 5 mg of diazepam 1 h before the procedure and local infiltration of the skin, subcutis, and liver capsule with 10 mL of 2% lidocaine just before needle insertion.
The biopsy was conducted under ultrasound guidance with a 16-gauge disposable Truecut needle with an automatic gun. After the procedure, patients were instructed to lie on their right side for 30 min and to stay in bed for an additional 2.5 h. They were allowed to leave the hospital 3 h later. Subjects were asked to grade the intensity of pain on the VAS at the end of the procedure (on needle removal); at 5, 10, 15, and 30 min after the procedure; and at 1, 2, 4, 6, 12, and 24 h after the procedure. They were also requested to localize their pain on a body scheme at each time point.
Statistical analysis used analysis of variance, linear regression, and Spearman correlations, with the use of Excel (Microsoft Corp., Redmond, WA), JMP, and SAS (SAS Institute, Cary, NC). P was considered significant at the 0.05 level. Data are presented as mean Ϯ sem.
Results
A total of 95 percutaneous liver biopsies were performed at our institution during the study period. Fifty-four subjects were included in the analysis. Their median age was 43 yr. Thirty-four were men, and 20 were women. Forty-seven subjects were having their first liver biopsy, two the second, and five the third. Their demographic and relevant medical data are presented in Table 1 . The other 41 subjects were not included because of failure to complete the demographic, general health, and Spielberger Anxiety questionnaires. This was because the questionnaires were presented in Hebrew, a language that many of the referred patients could not understand.
Sixty-nine percent of the patients reported pain immediately after the procedure. The percentage of patients in pain increased to a maximum (of 83%) at 30 min and gradually decreased thereafter. However, 47% of the patients were still in pain at 12 h and 39% at 24 h (Fig. 1A) . Pain intensity (VAS) followed a similar pattern of evolution: 2.8 Ϯ 04 immediately after the procedure, 4.2 Ϯ 0.5 at 30 min after the biopsy, 3.6 Ϯ 0.4 at 1 h, 2.4 Ϯ 0.5 at 2 h, and 2.0 or less at 4 -24 h after the biopsy (Fig. 1, A and B) . Thirtythree patients (61%) reported pain of at least moderate severity (VAS Ͼ4.0) during the first hour and 15 (28%) at 24 h.
Biopsy site pain was reported by 9 subjects, rightshoulder pain by 14 subjects, and pain in both sites by 24 subjects. The time course of pain at both sites followed a similar pattern, but higher pain intensities were reported in the right shoulder as compared with the biopsy site.
The median state anxiety level determined by the Spielberger Anxiety Questionnaire was 45 (range, 22-73). A significant correlation (Spearman) between state anxiety level before the biopsy and mean pain intensity during the first 6 h after the procedure was found (r ϭ 0.415; P ϭ 0.0001; Fig. 2) . Subjects who had high (above median) anxiety levels reported higher pain levels than did those with low (below median) anxiety levels (Fig. 3A) . It is noteworthy that women reported higher pain intensities than men throughout the entire follow-up period, although the difference between sexes was statistically significant (P ϭ 0.02) only at the 24-h time point (Fig. 3B) . Only four subjects were reluctant to undergo another biopsy under similar conditions in the future.
Discussion
The main finding of this study is that liver biopsy can produce pain for an extended period of time. Most patients reported pain immediately after the procedure, more than half were still in pain 4 hours later, and nearly 40% reported pain 24 hours after the procedure. This finding supports the results of a previous pilot study in which pain lasting for a day after liver biopsy was reported (12) . The importance herein lies in the fact that hepatologists generally do not regard pain during or after liver biopsy as a significant issue. It is true that the average reported pain intensity, in this study as well as in several others (3, 9, 12) , was mild to moderate. However, a significant proportion of the patients reported pain to be moderate or worse, lasting for several hours and in some cases for an entire day. This study also shows that local anesthetics, even at a reasonable dose, fail to produce sufficient immediate and late analgesia. Most of our patients, as well as 36%-47% of the patients in the Farrell et al. (3) group, were in pain at the end of the procedure while still under the effect of the local anesthetics. Not surprisingly, the number of patients in pain increased over the next hour, as the effect of the local anesthetics wore off. The type of anesthesia or sedation required for effective analgesia of patients undergoing liver biopsy has not yet been determined. Local anesthesia by itself is clearly not sufficient. Conscious sedation with midazolam has been reported to reduce pain and discomfort during and immediately after the procedure (4,5) but is neither highly recommended (7, 8) nor often used (3). Nitrous oxide/oxygen inhalation can also be an effective and safe alternative way of controlling the pain during and shortly after the procedure (6) .
Even if often and appropriately used, conscious sedation alone can reduce pain only during the procedure and for the immediate postbiopsy period. Because half of the patients are in pain for 4 hours, and some for as long as 24 hours, it is likely that liver biopsy may require a different pain management strategy from such procedures as bone marrow aspiration or lumbar puncture, which are usually painful only at the time of their performance. This should probably include the combination of substantial anesthesia or sedation during the procedure, followed by longer-term analgesia. Unfortunately, no data are available on the efficacy and safety of other treatments for this delayed pain. Controlled trials are therefore needed to determine whether simple analgesics, nonsteroidal antiinflammatory drugs, or perhaps even opioids, administered either before or after the procedure, can produce effective and safe pain control.
The right-shoulder pain after liver biopsy is well known to clinicians that perform these procedures but has never been fully characterized. In this regard, there are two observations in this study worth noting. The first is that right-shoulder pain is at least as common as, if not more common than, biopsy site pain. The second is that the course of the evolution of pain over time in both sites follows a similar pattern. In other words, pain in the right shoulder begins, reaches its peak, and subsides together with the biopsy site pain. This may indicate that the right-shoulder pain is likely to be a viscerosomatic referred pain, rather than an indication of a severe complication, such as intraabdominal bleeding. Partial support for this idea is provided by a previous study (13) in which a normal follow-up ultrasound was found in 10 patients who complained of postbiopsy pain. The conclusion of that study was that "post biopsy pain may not emanate from intraabdominal bleeding or diaphragmatic irritation." The biopsy site pain is likely to be a nociceptive pain that originates from the skin, the nociceptive innervated liver capsule (14) , or both.
Another interesting observation is the between-sex difference in the intensity of pain. Women tended to report higher pain levels than men at all time points tested. Similar tendencies among women to report higher levels of acute postoperative and experimental pain have been reported previously (15) (16) (17) . Higher pain levels in women after liver biopsy were reported in one study (9) , whereas severe pain was noted in 6 of 30 patients, all men, in another (12) . The cause for the sex differences in pain perception is unknown.
Finally, the linear correlation between the state anxiety level before the procedure and the pain level during the first six hours after the procedure is consistent with the results of previous studies. High anxiety levels have been shown to exacerbate acute postoperative pain (18) and labor pain (19) . This relationship may suggest that anxiolytic treatment before a procedure can reduce subsequent pain. In this study, all patients were premedicated with a standard dose of 5 mg of oral diazepam, which was most likely insufficient for at least some of them. One possible way to improve pain control, on the basis of our findings, is to assess the anxiety level before the procedure, to adjust the dose of the anxiolytic drug accordingly, to add conscious sedation to those who are at a high level of stress, to infiltrate the biopsy site with long-acting local anesthetics, and to administer adequate analgesics for as long as needed. This treatment approach still awaits validation. Figure 3 . A, Differences in pain intensities (represented by mean Ϯ sem) between subjects with high state anxiety levels (F) and subjects with low state anxiety levels (⅙) over time. B, Differences in pain intensities (represented by mean Ϯ sem) between women (F) and men (⅙) over time. VAS ϭ visual analog score.
